Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)
- 1 July 2021
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 152, 116-128
Abstract
No abstract availableKeywords
Funding Information
- Pfizer Inc Boulder
This publication has 27 references indexed in Scilit:
- Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.Journal of Clinical Oncology, 2020
- Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanomaEuropean Journal of Cancer, 2020
- Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutationsExpert Review of Clinical Pharmacology, 2019
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trialThe Lancet Oncology, 2018
- Health-Related Quality of LifeSurgical Oncology Clinics of North America, 2018
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2018
- Quality‐of‐life outcomes in patients with advanced melanoma: A review of the literaturePigment Cell & Melanoma Research, 2017
- Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialThe Lancet Oncology, 2015
- Beyond BRAF: where next for melanoma therapy?British Journal of Cancer, 2014
- The role of BRAF V600 mutation in melanomaJournal of Translational Medicine, 2012